Read + Share
Ozberk U, Esen SA, Sekmek S, Seven I, et al. Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer
regardless of platinum sensitivity. Anticancer Drugs 2025 Dec 18. doi: 10.1097/CAD.0000000000001798.
PMID: 41430637
|
 |
|
Ozberk U, Esen SA, Sekmek S, Seven I, et al. Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer
regardless of platinum sensitivity. Anticancer Drugs 2025 Dec 18. doi: 10.1097/CAD.0000000000001798.
PMID: 41430637
|
|
|
|